CBDual Biotechnology Corp (subsidiary of OTC: CBDG) to Offer ORALDNA(R) Testing to Improve Oral and Systemic Health

Author's Avatar
Aug 09, 2019
Article's Main Image

THOUSAND OAKS, CA / ACCESSWIRE / August 9, 2019 / CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK:CBDG) developer of CBD based oral health products, today announced - that the Company is now offering a powerful new tool to help with gum disease diagnosis and treatment. A simple rinse test from OralDNA® Labs identifies individual genetic susceptibility to periodontal disease. With this information, clinicians are able to establish which patients are at increased risk for more severe periodontal infections, allowing personalized therapy and treatment. All salivary diagnostic tests can be ordered from the same simple oral rinse collection, disease-causing bacteria and helps personalize doctor prescribed treatment. An extensive evaluation by the Company’s dental clinicians established that the use of OralDNA® testing improves oral health outcomes and allows patients to make more informed choices on both professional and at-home care. CBDual Biotechnology is getting ready to begin clinical trials for its CBD based dental mouthwash. Published clinical research suggests that CBD may be useful to control bone resorption and gums inflammation during progression of experimental periodontitis in laboratory animals.